Title: Clinical value of combined detection of the serum tumor marker in the diagnosis of breast cancer
Abstract: Objective To investigate the clinical value of the combined detection of the serum tumor marker(including CA15-3,CYFRA21-1,TSGF and CA19-9) in the diagnosis and treatment of breast cancer.Methods The serum samples of 182 patients with breast cancer were collected,and tumor markers CA15-3,CYFRA21-1,TSGF and CA19-9 were detected with electrochemiluminescence method,and TSGF was detected with chemocolorimetry method.The results were compared with 80 cases of benign breast disease and 50 normal cases.Results The serum levels of CA15-3,TSGF,OPN and CA125 of breast cancer patients were significantly higher than those of the benign breast disease and the normal cases (P < 0.01 ).The sensitivity of CA15-3 to breast cancer was 60.4% ( 110/182),with a specificity of 90.0% (45/50),the sensitivity of CYFRA21-1 was 72.5 ( 132/182 ),with a specificity of 86.0% (43/50),the sensitivity of TSGF was 74.7% ( 136/182 )with a specificity of 92.0% (46/50),and the sensitivity of CA19-9 was 36.3% (66/182),with a specificity of 84.0% (42/50).The sensitivity of the combination detection of above tumor markers was 91.8% ( 167/182 ),with a specificity of 84.0% (42/50).Conclusions CA15-3,CYFRA21-1,TSGF and CA19-9 have certain diagnostic value in breast cancer complementarily,and the combined detection can significantly improve the sensitivity and accuracy of breast cancer diagnosis.
Key words:
Breast cancer; Serum tumor marker; Combined detection; Value
Publication Year: 2012
Publication Date: 2012-08-25
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot